التفاصيل البيبلوغرافية
| العنوان: |
Electronic patient-reported monitoring of symptoms during follow-up of ovarian cancer patients: a feasibility study |
| المؤلفون: |
Fiona Kennedy, Leanne Shearsmith, Marie Holmes, Zoe Rogers, Rob Carter, Uschi Hofmann, Galina Velikova |
| المصدر: |
BMC Cancer, Vol 22, Iss 1, Pp 1-15 (2022) |
| بيانات النشر: |
BMC, 2022. |
| سنة النشر: |
2022 |
| المجموعة: |
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: |
Ovarian cancer, Follow-up, Electronic patient-reported outcomes, Feasibility study, Compliance, Acceptability, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: |
Abstract Background Ovarian cancer patients require monitoring for relapse. Innovative follow-up methods are increasingly being explored. An electronic patient-reported outcome (ePRO) follow-up pathway was developed for women treated for ovarian cancer. This feasibility study explored patient acceptability and compliance. Methods A single-arm non-blinded prospective feasibility study was undertaken at two hospitals. Participants were women who had completed treatment for ovarian cancer whose clinician was happy for them to be monitored remotely. Automated 3-monthly reminders were sent to participants to complete an ePRO questionnaire and obtain blood tests. Participants were reviewed over the phone by their clinical nurse specialist instead of attending clinic-based follow-up. The primary outcome was compliance (expected ePRO completions/blood tests) across the 12-month study period. Secondary outcomes were recruitment, attrition, resource use, symptom severity/alerts and patient acceptability. Results Twenty-four women consented (50% consent rate), and 13 remained on study at 12 months. Seven women relapsed, 3 chose to withdraw, and 1 withdrew for other clinical reasons. ePRO compliance was high and consistent at 75-82%, although the two hospitals differed. Adherence to the clinical protocol was evident for blood tests and contacts with staff (fewer visits, more phonecalls compared to an earlier audit). End-of-study feedback indicated high patient satisfaction. Conclusions Remote ePRO follow-up for ovarian cancer is feasible and acceptable to patients who are able and willing to participate. However, the low recruitment rate (ineligible + declined) indicate it is not suitable/acceptable to all patients immediately post-treatment. Further large-scale research and implementation work is required, especially in a post-COVID era. Trial registration ClinicalTrials.gov ID: NCT02847715 (first registered 19/05/2016). |
| نوع الوثيقة: |
article |
| وصف الملف: |
electronic resource |
| اللغة: |
English |
| تدمد: |
1471-2407 |
| Relation: |
https://doaj.org/toc/1471-2407 |
| DOI: |
10.1186/s12885-022-09817-5 |
| URL الوصول: |
https://doaj.org/article/67b8a43f96e84171a486bc88759e9da0 |
| رقم الانضمام: |
edsdoj.67b8a43f96e84171a486bc88759e9da0 |
| قاعدة البيانات: |
Directory of Open Access Journals |
Full Text Finder